AR and neoplasm: The androgen receptor is an emerging prognostic marker for breast cancer, with a recent meta-analysis by Bozovic-Spasojevic et al. of 13 studies (n = 5648 patients) finding tumor AR expression to be associated with improved DFS in the multivariate analysis (HR = 0.46, 95% CI 0.37–0.58) [12].